Journal
RAPID COMMUNICATIONS IN MASS SPECTROMETRY
Volume -, Issue -, Pages -Publisher
WILEY
DOI: 10.1002/rcm.9130
Keywords
-
Funding
- University of Leeds [P5, P3]
- Biotechnology and Biological Sciences Research Council
Ask authors/readers for more resources
This study utilized X-ray crystallography and biochemical methods to determine the binding modes of type I and type II kinase inhibitors with FGFR1, and demonstrated distinct differences in the folding landscape of FGFR1 for the two types of inhibitors using ESI-IMS-MS technology. The results suggest that conformational variations detected by ESI-IMS-MS can effectively distinguish between type I and type II inhibitors, providing a rapid and high-throughput screening method for novel kinase inhibitors.
Rationale The protein kinase FGFR1 regulates cellular processes in human development. As over-activity of FGFR1 is implicated with cancer, effective inhibitors are in demand. Type I inhibitors, which bind to the active form of FGFR1, are less effective than type II inhibitors, which bind to the inactive form. Screening to distinguish between type I and type II inhibitors is required. Methods X-ray crystallography was used to indicate whether a range of potential inhibitors bind to the active or inactive FGFR1 kinase conformation. The binding affinity of each ligand to FGFR1 was measured using biochemical methods. Electrospray ionisation - ion mobility spectrometry - mass spectrometry (ESI-IMS-MS) in conjunction with collision-induced protein unfolding generated a conformational profile of each FGFR1-ligand complex. The results indicate that the protein's conformational profile depends on whether the inhibitor is type I or type II. Results X-ray crystallography confirmed which of the kinase inhibitors bind to the active or inactive form of FGFR1 kinase. Collision-induced unfolding combined with ESI-IMS-MS showed distinct differences in the FGFR1 folding landscape for type I and type II inhibitors. Biochemical studies indicated a similar range of FGFR1 affinities for both types of inhibitors, thus providing confidence that the conformational variations detected using ESI-IMS-MS can be interpretated unequivocally and that this is an effective screening method. Conclusions A robust ESI-IMS-MS method has been implemented to distinguish between the binding mode of type I and type II inhibitors by monitoring the conformational unfolding profile of FGFR1. This rapid method requires low sample concentrations and could be used as a high-throughput screening technique for the characterisation of novel kinase inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available